陈志龙：二级教授、博士生导师。
为第二军医大学药学学士、医学博士（药学专业），曾先后在中科院上海有机化学研究所、澳大利亚Central Queensland University、英国The University of Liverpool进行博士后研究。曾任第二军医大学防护医学教研室主任、学科带头人。现为bwin体育生物医药研究组课题组长，PI，药物化学与药理学教授，博士生导师。
为中国光学会激光医学分会常务理事；上海药学会理事；上海生化药物专业委员会副主任委员；上海药物化学专业委员会委员；上海药学会产学研创新工作委员会委员；上海市药学会医院药学专委会委员；上海药理学会治疗药物监测研究专委会委员；上海市抗癌协会肿瘤药学专委会委员；上海市医院协会临床药事管理专委会委员；上海市医学会第六届医疗事故鉴定专家库成员；上海市医学会第四届预防接种异常反应鉴定专家库成员。
为国家科学技术奖励评审专家；科技部重大重点专项评审专家；国家自然科学基金评审专家；教育部计划项目与博士点基金评审专家；上海市科委项目评审专家。
发表论文340余篇。出版英文专著2部、中文专著3部。申请国家发明专利90余项。
研究方向:
（1）人工智能(AI)和计算机辅助 (CADD)新药研发；
（2）光敏新药研发及光动力疗法的基础与应用研究（如抗肿瘤、抗鲜红斑痣、抗类风湿性关节炎、抗菌抗病毒作用等）；
（3）靶向药物研究（如抗肿瘤靶向新药研究；降压新药研究；叶酸、多肽、单克隆抗体等靶向分子导向的新药研究）；
（4）多功能、多模态药物纳米靶向制剂研究；
（5）中药与天然药物研究；
（6）药物代谢、药理毒理学及临床药学研究。
（7）医学成像试剂研究。
主要研究成果：
（1）在光敏新药研制及光动力疗法基础与应用研究领域做出了出色成绩，处于国内领先，国际上有一定影响力。有2个光敏新药进入临床研究，1个进行临床前研究。
（2）创制了1个高效、长效、低毒的沙坦类降压新药，正在进行临床前研究。
（3）作为主要成员参与研发的国家一类抗肿瘤新药CM-Na已获准上市（该项目获国家发明二等奖）、光敏新药血卟啉单甲醚已获准上市。
（4）发现了一个新的有机化学反应--三联吡啶的重排反应，该反应在制备具有特殊光化学与光生物医学性能的三联吡啶化合物及其金属配合物领域具有重要用途。
（5）在药物纳米靶向传递剂型研究领域，在新药药理评价模型构建、新药评价方法研究等领域也做出了一定成绩。
（6）在新药仿制与医药中间体制备工艺研究领域做出了出色成绩。茶碱类系列产品、氨基葡萄糖系列产品在企业实现产业化，产值过亿元。
荣誉及获奖情况：
1、第二军医大学 “学习成才十佳先进个人”；
2、上海市“浦江人才”；
3、南京市“创新创业人才”；
4、上海市“优秀学术技术带头人”；
5、嘉兴市“科技领军人才”
6、主持项目“光敏新药与试剂的研制及光动力疗法的基础与应用研究”获上海市药学科技二等奖（2012年）。
7、主持项目“光敏新药与试剂的研制及光动力疗法的基础与应用研究”获中国药学科技三等奖（2013年）。
8、参与项目（第二负责人）“光动力治疗皮肤病关键技术创新及推广应用”获中华医学科技三等奖（2017年）。
9、主持，平湖市创新创业大赛一等奖----光敏新药与试剂及降压新药研究开发（2018年）。
承担的项目：
承担各类项目90余项，其中主持50余项，参与30余项。如主持各类人才基金5项、国家自然科学基金6项、军队医药卫生重大课题1项、上海市科委与教委重点项目7项、国际合作项目8项等。参与国家与国际重要课题6项，如国家新药创制重大专项、国家自然科学基金重点项目等；指导团队成员获国家自然基金5项、国家与上海市博士后基金11项、上海市科委重点项目8项等。部分课题如下：
1、国家自然科学基金（编号：21372042；30973611；30271534；30070862；29872055；21977016等）。
2、上海市优秀学术技术带头人人才计划基金（编号：15XD1523400）。
3、上海市浦江人才计划基金（编号：06PJ14001）。
4、上海市科委重大重点基金（编号：13431900700；15411960400；14140903500；17431902600；14431906200；15431904100；21430730100等）。
5、科技部与上海市国际科技合作基金（编号：6-11、11BA1400700、13430722300、17430711900、17430741800、18430713000、20490740400、21430730100等）。
6、军队医药卫生重大项目（编号01L054）。
7、上海市教委重点项目基金（编号：10ZZ45）。
发表论文：发表论文340余篇，部分论文如下：
1. Tabbisa Namulinda, Zhi-Long Chen*, et al. Antibacterial and anticancer activities of green synthesized silver nanoparticles using Photinia glabra fruit extract. Nanomedicine, 2023, 18, (14): 987-1002. (SCI, Q1)
2. Man Yi Li, Zhi Long Chen*, et al. The bromoporphyrins as promising anti-tumor photosensitizers in vitro. Photochemical & Photobiological Sciences, 2023, 22, 427-439. (SCI, Q2)
3. Man Yi Li, Zhi Long Chen*, et al, The biological activities of 5,15-diaryl-10,20-dihalogeno porphyrins for photodynamic therapy. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2335-2346. (SCI, Q2)
4. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new fluorinated pyropheophorbide-a derivatives for photodynamic therapy. Dyes and Pigments, 2022, 197, 109932.(SCI, Q1,TOP期刊)
5. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new pyropheophorbide-a derivatives for CAIX-targeted photodynamic therapy. Dyes and Pigments, 2022, 203,110328.(SCI, Q1, TOP期刊).
6. Faiza Sajjad, Zhi-Long Chen*, et al. Incorporation of green emission polymer dots into pyropheophorbide-α enhance the PDT effect and biocompatibility. Photodiagnosis and Photodynamic Therapy, 2022, 37, 102562.（SCI, Q3）
7. Man-Yi Li, Ying-Hua Gao, Zhi-Long Chen*, et al. Synthesis and evaluation of novel fluorinated hematoporphyrin ether derivatives for photodynamic therapy. Bioorganic Chemistry, 2021, 107, 104528.(SCI, Q1,TOP期刊)
8. Faiza Sajjad, Zhi-Long Chen*, et al. Synthesis and invitro PDT evaluation of red emission polymer dots (R-CPDs) and pyropheophorbide-α conjugates. Scientific Reports. 2021, 11, 10013. (SCI, Q2)
9. Zhuo Wu, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of novel fluoro-substituted benzimidazole derivatives with anti-hypertension activities. Bioorganic Chemistry, 2020, 101, 104042. (SCI, Q1,TOP期刊)
10.Ying-Hua Gao, Zhi-Long Chen*. Synthesis and pharmacological evaluation of chlorin derivatives for photodynamic therapy of cholangiocarcinoma. European Journal of Medicinal Chemistry, 2020,189, 112049.(SCI, Q1,TOP期刊)
11. Ying-Hua Gao, Zhi-Long Chen*, Synthesis and evaluation of novel chlorophyll a derivatives as potent photosensitizers for photodynamic therapy. European Journal of Medicinal Chemistry, 2020, 187, 111959.(SCI, Q1,TOP期刊)
12.Ying-Hua Gao, Vanda Lovreković, Zhi-Long Chen*, et al. The photodynamic activities of dimethyl 131-[2-(guanidinyl)ethylamino] chlorin e6 photosensitizers in A549 tumor. European Journal of Medicinal Chemistry, 2019, 177, 144-152. (SCI, Q1,TOP期刊)
13. Zhuo Wu, Yi-Jia Yan, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of AT1 receptor blockers derived from 6-substituted aminocarbonyl benzimidazoles. European Journal of Medicinal Chemistry, 2019,181,111553. (SCI, Q1,TOP期刊)
14. Zhuo Wu, Xiao-Lu Bao, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of 6-benzoxazole benzimidazole derivatives with anti-hypertension activities. ACS Medicinal Chemistry Letters, 2019, 10, 40 - 43. (SCI, Q2)
15. Wei Zhu, Ying-Hua Gao, Zhi-Long Chen*, et al. Comparison between porphin, chlorin and bacteriochlorin derivatives for photodynamic therapy: Synthesis, photophysical properties, and biological activity. European Journal of Medicinal Chemistry, 2018, 160, 146-156. (SCI, Q1,TOP期刊)
16. Sonja Srdanovic, Davor Margetic*, Zhi-Long Chen*. The photodynamic activity of 131-[2’-(2-pyridyl)ethylamine] chlorin e6 photosensitizer in human esophageal cancer. Bioorganic & Medicinal Chemistry Letters. 2018, 28(10): 1785-1791. (SCI, Q2)
17. Wei Zhu, Yi-Jia Yan, Zhi-Long Chen*, et al. Synthesis and biological evaluation of 173-dicarboxylethyl pyropheophorbide-a amide derivatives for photodynamic therapy. Bioorganic & Medicinal Chemistry Letters. 2018, 28: 2784-2788. (SCI, Q2)
18. Ping-Yong Liao, Zhi-Long Chen*, et al. Synthesis of 2-morpholinetetraphenylporphyrins and their photodynamic activities. Bioorganic Chemistry, 2017, 71: 299 - 304.(SCI, Q1,TOP期刊)
19. Li Wang, Wei Zhu, Zhi-Long Chen*, et al. Preparation of a chlorophyll derivative and investigation of its photodynamic activities against cholangiocarcinoma. Biomedicine & Pharmacotherapy. 2017, 92: 285-292. (SCI, Q1,TOP期刊)
20. Lei-Lei Bao, Donal F. O’Shea*, Zhi-Long Chen*, et al. In vitro and in vivo evaluation of a pyropheophorbide-a derivative as a potential photosensitizer for age-related macular degeneration. Biomedicine & Pharmacotherapy, 2017, 88: 1220-1226. (SCI, Q1,TOP期刊)
21.Xiaolu Bao, Weibo Zhu, Zhilong Chen*, et al. Design, synthesis and evaluation of novel potent angiotensin II receptor 1 antagonists. European Journal of Medicinal Chemistry, 2016, 123,115-127.(SCI, Q1,TOP期刊)
22. Weibo Zhu, Xiaolu Bao, Zhilong Chen*, et al. N-phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2016, 115,161-178.(SCI, Q1,TOP期刊)
23. Xiang-Hua Zhang, Li-Jun Zhang, Zhi-Long Chen*, et al. Photodynamic efficiency of a chlorophyll-a derivative in vitro and in vivo. Biomedicine & Pharmacotherapy, 2016, 81, 265-272. (SCI, Q1,TOP期刊)
24. Li-Jun Zhang, Yi-Jia Yan, Zhi-Long Chen*, et al. Antitumor activity evaluation of meso-tetra (pyrrolidine substituted) pentylporphin-mediated photodynamic therapy in vitro and in vivo. Journal of Photochemistry & Photobiology, B: Biology. 2016, 163:224-231. (SCI, Q1,TOP期刊)
25. Ping-Yong Liao, Ying-Hua Gao, Zhi-Long Chen*, et al. Tetraphenylporphyrin derivatives possessing piperidine group as potential agents for photodynamic therapy. Journal of Photochemistry & Photobiology, B: Biology. 2016, 165: 213-219. (SCI, Q1)
26. Hongyu Tan, Ioannis Houpis, Zhilong Chen*, et al. Olefin preparation via palladium-catalyzed oxidative de-azotative and de-sulfitative internal cross-coupling of sulfonylhydrazones. Organic Letters, 2015,17(14)：3548-3551.(SCI, Q1,TOP期刊)
27. Dan Wu, Zhi-Long Chen and Donal F. O’Shea, et al. Synthesis and assessment of a maleimide functionalized BF2 azadipyrromethene near-infrared fluorochrome. Chemical Communications, 2015, 51(93): 16667-16670.(SCI, Q1,TOP期刊)
28. Li-Jun Zhang, Zhi-Long Chen*, et al. Evaluation of a bacteriochlorin-based photosensitizer’s anti-tumor effect in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2015, 141（11）: 1921-1930. (SCI, Q2)
29. Hongyu Tan, Zhilong Chen*, et al. Palladium-catalyzed coupling of sulfonylhydrazones with heteroaromatic 2-amino-halides (Barluenga Reaction): exploring the electronics of the sulfonylhydrazone. Organic Process Research & Development. 2015, 19(8), 1044-1048. (SCI, Q1)
30. Xiao-Lu Bao, Zhi-Long Chen*, et al. Design, synthesis and evaluation of novel angiotensin II receptor 1 antagonists with antihypertensive activities. RSC Advances, 2017, 7: 26401-26410. (SCI, Q2)
31. Pingyong Liao, Zhilong Chen*, et al. Synthesis, characterization and biological evaluation of a novel biscarboxymethyl-modified tetraphenylchlorin compound for photodynamic therapy. RSC Advances, 2016, 6: 26186 - 26191. (SCI, Q2)
32. Mengshi Yang, Zhilong Chen, et al. Photodynamic therapy of drug-resistant human colon adenocarcinoma using verteporfin loaded TPGS nanoparticle with tumor homing and penetrating peptide functionalized. RSC Advances, 2016, 6: 100984-100992. (SCI, Q2)
33.Dan Wu, Zhi-long Chen, et al. Strained alkyne substituted near infrared BF2 azadipyrromethene fluorochrome. RSC Advances, 2016, 6: 87373-87379. (SCI, Q2)
34. Wei Zhu, Ying-Hua Gao, Zhi-Long Chen*, et al. Synthesis and evaluation of new 5-aminolevulinic acid derivatives as prodrugs of protoporphyrin for photodynamic therapy. Photochemical & Photobiological Sciences. 2017, 16: 1623-1630. (SCI, Q2)
35. Ping-Yong Liao, Xinrong Wang, Zhi-Long Chen*, et al. Synthesis, photophysical properties and biological evaluation of b-alkylaminoporphyrin for photodynamic therapy. Bioorganic & Medicinal Chemistry, 2016, 24(22): 6040-6047. (SCI, Q2)
36. Xiaolu Bao, Weibo Zhu, Zhi-Long Chen*, et al. Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs. Bioorganic & Medicinal Chemistry, 2016, 24(9): 2023-2031. (SCI, Q2)
国际交流与合作：
与英国利物浦大学、爱尔兰都柏林大学、爱尔兰皇家外科学院、美国新泽西立大学、澳大利亚中昆士兰大学、克罗地亚鲁德尔博斯科维奇研究所、俄罗斯国家科学中心、南非罗德斯大学等多所大学与研究所有合作关系。
讲授课程:
新药研究开发学、基础有机化学实验
研究团队:
团队成员30余名，含博士助手2名、化学与生物医学博士后2名、博士硕士研究生二十余名、留学生6名。
博士后招聘：
招收药学、化学、生物学、医学、材料学等专业博士后。
博士、硕士研究生招生：
在化学、生物化学与分子生物学、生物与医药、生物医学工程、材料学等专业的博士、硕士点，招收药学、化学、生物学、医学、材料学等专业背景研究生。
就业前景：
本课题组研究方向就业前景好。
电话：021-67792654；E-mail：zhlchen@dhu.edu.cn
Curriculum Vitae
Prof. Zhi-Long Chen
Department of Pharmaceutical Science and Technology,
College of Biology and Medical Engineering
Donghua University. Shanghai, China
Position:
Distinguished Professor of Medicinal Chemistry and Pharmacology.
Director of Department of Pharmaceutical Science and Technology.
Personal Statement:
Zhi-Long Chen got his B.Sc. in 1991 and Ph.D. of Medicinal Chemistry from Second Military Medical University in 1996. He once worked as postdoctoral fellow in Shanghai Institute of Organic Chemistry, Chinese Academy of Science (China); in Central Queensland University (Australia) and the University of Liverpool (England).
He is the vice chair of Shanghai Bio-drugs Association. He also serves as committee member of Shanghai Association of Medicinal Chemistry, Shanghai Association of Pharmacy; committee member of Chinese Association of Laser Medicine; committee member of Shanghai Hospital Pharmacy Association; committee member of Therapeutic Drug Monitoring Research Committee of Shanghai Pharmacological Society; Committee of Shanghai Anti-Cancer Association and Clinical Pharmacy Management Committee of Shanghai Hospital Association; the member of Expert Pool for Shanghai Medical Association; the member of Medical Accident Appraisal and Identification of Abnormal Reactions to Vaccination of Shanghai Medical Association.
Prof. Chen has published more than 340 papers and 5 academic books, applied more than 90 patents. His projects were supported by more than 90 grants from Chinese Government and Shanghai Governments. More than 20 products were prepared and used in factories.
He got the award of “Shanghai Pujiang Talents” in 2008 and “Shanghai outstanding science and technology group leader” in 2014 from Shanghai Science and Technology Bureau.
Research interests:
1. The discovery of new drug based on artificial intelligence (AI) and computer-aided drug design (CADD).
2. The discovery and development of new photosensitizer drugs in photodynamic therapy, and photo-diagnosis to tumor, senile macular degeneration, actinic keratosis, port-wine stains, rheumatoid arthritis.
3. The discovery and development of new targeted drugs, including new anti-tumor drugs，new antihypertensive drugs and new molecular targeted drugs (folic acid, peptides, monoclonal antibodies, etc.).
4. The discovery of targeted nano drug delivery system with multifunction and multimodal effects.
5. The discovery of new drugs from natural products.
6. Studies on the pharmacology, toxicology, pharmacokinetics and mechanism of new drugs.
7. The discovery of new medical imaging agents.
The achievements of new drug discovery:
1. One new photodynamic anti-tumor drug was discovered and was in pre-clinical evaluation.
2. New anti-hypertension drug Intersartan was discovered with high efficiency, long-lasting effect and was in pre-clinical evaluation.
3. As a major participant, new antitumor drug CM-Na was discovered and approved by Chinese SFDA, which is the first radio-sensitizing anti-tumor drug on sale now in the world.
4. As a major participant, new photodynamic drug hermatoporphyrin dimethyl ether (HMME) was discovered and was approved by SFDA to use in clinics. (SFDA approval No. H20120076).
Awards:
1. “Shanghai Pujiang Talents” in 2008 from Shanghai Science and Technology Bureau.
2. “Shanghai outstanding science and technology group leader” in 2014 from Shanghai Science and Technology Bureau.
3. Zhi-Long Chen, Wen-Hui Chen, Yi-Jia Yan, etc. “Studies on the discovery of new photodynamic drugs and reagents, on the fundamental research and application of photodynamic therapy” got the awards from Shanghai Pharmacy Association in 2012.
4. Zhi-Long Chen, Wen-Hui Chen, Yi-Jia Yan, etc. “Studies on the discovery of new photodynamic drugs and reagents, on the fundamental research and application of photodynamic therapy” got the awards from Chinese pharmacy Association in 2013.
5. Xiu-Li Wang, Zhi-Long Chen, Heng Gu, etc. “The key technic innovations and their application of photodynamic therapy in skin diseases” got the award from Chinese Medicine Association in 2017.
6. The first prize of “Innovation and Entrepreneurship Competition of Pinghu city” in 2018.
Grants:
More than 90 projects were supported by Chinese central government and Shanghai city government and other city governments. Recent Grants:
1. Grants from National Natural Science Foundation of China（No. 21372042；30973611；30271534；30070862；29872055；21977016, et al）.
2. Grant from “Shanghai outstanding science and technology group leader” programme，（No.15XD1523400）.
3. Grant from “Shanghai Pujiang Talent” programme（No. 06PJ14001）.
4. The key grants from Shanghai government (No. 21430730100；17431902600；15411960400；15431904100；14431906200；14140903500；13431900700, et al)
5. Shanghai International collaboration grant (No. 17430711900; 18430713000, Collaborate with Prof. Davor Margetic, Croatia).
6. Shanghai international collaboration grant (No. 20490740400, collaborate with Prof.Ni Ni Than and Dr. Thin Wut Soe, University of Yangon, Burma）
7. Shanghai international collaboration grant（No. 17430711900, Collaborate with Dr. Nguyen Thi Phuong Anh, Hue University,Vietnam）.
8. Shanghai international collaboration grant (No. 13430722300, Collaborate with Prof. Donal O’Shea, University of Dublin, Ireland）.
9. Shanghai international collaboration grant (No. 21430730100, Collaborate with Dr. X. F. Wu, University of Liverpool, England）.
Publication: more than 340 papers were published.
Some Recent publications:
1. Tabbisa Namulinda, Zhi-Long Chen*, et al. Antibacterial and anticancer activities of green synthesized silver nanoparticles using Photinia glabra fruit extract. Nanomedicine, 2023, 18, (14): 987-1002. (SCI, Q1)
2. Man Yi Li, Zhi Long Chen*, et al. The bromoporphyrins as promising anti-tumor photosensitizers in vitro. Photochemical & Photobiological Sciences, 2023, 22, 427-439. (SCI, Q2)
3. Man Yi Li, Zhi Long Chen*, et al, The biological activities of 5,15-diaryl-10,20-dihalogeno porphyrins for photodynamic therapy. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2335-2346. (SCI, Q2)
4. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new fluorinated pyropheophorbide-a derivatives for photodynamic therapy. Dyes and Pigments, 2022, 197, 109932.(SCI, Q1,TOP期刊)
5. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new pyropheophorbide-a derivatives for CAIX-targeted photodynamic therapy. Dyes and Pigments, 2022, 203,110328.(SCI, Q1, TOP期刊).
6. Faiza Sajjad, Zhi-Long Chen*, et al. Incorporation of green emission polymer dots into pyropheophorbide-α enhance the PDT effect and biocompatibility. Photodiagnosis and Photodynamic Therapy, 2022, 37, 102562.（SCI, Q3）
7. Man-Yi Li, Ying-Hua Gao, Zhi-Long Chen*, et al. Synthesis and evaluation of novel fluorinated hematoporphyrin ether derivatives for photodynamic therapy. Bioorganic Chemistry, 2021, 107, 104528.(SCI, Q1,TOP期刊)
8. Faiza Sajjad, Zhi-Long Chen*, et al. Synthesis and invitro PDT evaluation of red emission polymer dots (R-CPDs) and pyropheophorbide-α conjugates. Scientific Reports. 2021, 11, 10013. (SCI, Q2)
9. Zhuo Wu, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of novel fluoro-substituted benzimidazole derivatives with anti-hypertension activities. Bioorganic Chemistry, 2020, 101, 104042. (SCI, Q1,TOP期刊)
10.Ying-Hua Gao, Zhi-Long Chen*. Synthesis and pharmacological evaluation of chlorin derivatives for photodynamic therapy of cholangiocarcinoma. European Journal of Medicinal Chemistry, 2020,189, 112049.(SCI, Q1,TOP期刊)
11. Ying-Hua Gao, Zhi-Long Chen*, Synthesis and evaluation of novel chlorophyll a derivatives as potent photosensitizers for photodynamic therapy. European Journal of Medicinal Chemistry, 2020, 187, 111959.(SCI, Q1,TOP期刊)
12.Ying-Hua Gao, Vanda Lovreković, Zhi-Long Chen*, et al. The photodynamic activities of dimethyl 131-[2-(guanidinyl)ethylamino] chlorin e6 photosensitizers in A549 tumor. European Journal of Medicinal Chemistry, 2019, 177, 144-152. (SCI, Q1,TOP期刊)
13. Zhuo Wu, Yi-Jia Yan, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of AT1 receptor blockers derived from 6-substituted aminocarbonyl benzimidazoles. European Journal of Medicinal Chemistry, 2019,181,111553. (SCI, Q1,TOP期刊)
14. Zhuo Wu, Xiao-Lu Bao, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of 6-benzoxazole benzimidazole derivatives with anti-hypertension activities. ACS Medicinal Chemistry Letters, 2019, 10, 40 - 43. (SCI, Q2)
15. Wei Zhu, Ying-Hua Gao, Zhi-Long Chen*, et al. Comparison between porphin, chlorin and bacteriochlorin derivatives for photodynamic therapy: Synthesis, photophysical properties, and biological activity. European Journal of Medicinal Chemistry, 2018, 160, 146-156. (SCI, Q1,TOP期刊)
16. Sonja Srdanovic, Davor Margetic*, Zhi-Long Chen*. The photodynamic activity of 131-[2’-(2-pyridyl)ethylamine] chlorin e6 photosensitizer in human esophageal cancer. Bioorganic & Medicinal Chemistry Letters. 2018, 28(10): 1785-1791. (SCI, Q2)
17. Wei Zhu, Yi-Jia Yan, Zhi-Long Chen*, et al. Synthesis and biological evaluation of 173-dicarboxylethyl pyropheophorbide-a amide derivatives for photodynamic therapy. Bioorganic & Medicinal Chemistry Letters. 2018, 28: 2784-2788. (SCI, Q2)
18. Ping-Yong Liao, Zhi-Long Chen*, et al. Synthesis of 2-morpholinetetraphenylporphyrins and their photodynamic activities. Bioorganic Chemistry, 2017, 71: 299 - 304.(SCI, Q1,TOP期刊)
19. Li Wang, Wei Zhu, Zhi-Long Chen*, et al. Preparation of a chlorophyll derivative and investigation of its photodynamic activities against cholangiocarcinoma. Biomedicine & Pharmacotherapy. 2017, 92: 285-292. (SCI, Q1,TOP期刊)
20. Lei-Lei Bao, Donal F. O’Shea*, Zhi-Long Chen*, et al. In vitro and in vivo evaluation of a pyropheophorbide-a derivative as a potential photosensitizer for age-related macular degeneration. Biomedicine & Pharmacotherapy, 2017, 88: 1220-1226. (SCI, Q1,TOP期刊)
21.Xiaolu Bao, Weibo Zhu, Zhilong Chen*, et al. Design, synthesis and evaluation of novel potent angiotensin II receptor 1 antagonists. European Journal of Medicinal Chemistry, 2016, 123,115-127.(SCI, Q1,TOP期刊)
22. Weibo Zhu, Xiaolu Bao, Zhilong Chen*, et al. N-phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2016, 115,161-178.(SCI, Q1,TOP期刊)
23. Xiang-Hua Zhang, Li-Jun Zhang, Zhi-Long Chen*, et al. Photodynamic efficiency of a chlorophyll-a derivative in vitro and in vivo. Biomedicine & Pharmacotherapy, 2016, 81, 265-272. (SCI, Q1,TOP期刊)
24. Li-Jun Zhang, Yi-Jia Yan, Zhi-Long Chen*, et al. Antitumor activity evaluation of meso-tetra (pyrrolidine substituted) pentylporphin-mediated photodynamic therapy in vitro and in vivo. Journal of Photochemistry & Photobiology, B: Biology. 2016, 163:224-231. (SCI, Q1,TOP期刊)
25. Ping-Yong Liao, Ying-Hua Gao, Zhi-Long Chen*, et al. Tetraphenylporphyrin derivatives possessing piperidine group as potential agents for photodynamic therapy. Journal of Photochemistry & Photobiology, B: Biology. 2016, 165: 213-219. (SCI, Q1)
26. Hongyu Tan, Ioannis Houpis, Zhilong Chen*, et al. Olefin preparation via palladium-catalyzed oxidative de-azotative and de-sulfitative internal cross-coupling of sulfonylhydrazones. Organic Letters, 2015,17(14)：3548-3551.(SCI, Q1,TOP期刊)
27. Dan Wu, Zhi-Long Chen and Donal F. O’Shea, et al. Synthesis and assessment of a maleimide functionalized BF2 azadipyrromethene near-infrared fluorochrome. Chemical Communications, 2015, 51(93): 16667-16670.(SCI, Q1,TOP期刊)
28. Li-Jun Zhang, Zhi-Long Chen*, et al. Evaluation of a bacteriochlorin-based photosensitizer’s anti-tumor effect in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2015, 141（11）: 1921-1930. (SCI, Q2)
29. Hongyu Tan, Zhilong Chen*, et al. Palladium-catalyzed coupling of sulfonylhydrazones with heteroaromatic 2-amino-halides (Barluenga Reaction): exploring the electronics of the sulfonylhydrazone. Organic Process Research & Development. 2015, 19(8), 1044-1048. (SCI, Q1)
30. Xiao-Lu Bao, Zhi-Long Chen*, et al. Design, synthesis and evaluation of novel angiotensin II receptor 1 antagonists with antihypertensive activities. RSC Advances, 2017, 7: 26401-26410. (SCI, Q2)
31. Pingyong Liao, Zhilong Chen*, et al. Synthesis, characterization and biological evaluation of a novel biscarboxymethyl-modified tetraphenylchlorin compound for photodynamic therapy. RSC Advances, 2016, 6: 26186 - 26191. (SCI, Q2)
32. Mengshi Yang, Zhilong Chen, et al. Photodynamic therapy of drug-resistant human colon adenocarcinoma using verteporfin loaded TPGS nanoparticle with tumor homing and penetrating peptide functionalized. RSC Advances, 2016, 6: 100984-100992. (SCI, Q2)
33.Dan Wu, Zhi-long Chen, et al. Strained alkyne substituted near infrared BF2 azadipyrromethene fluorochrome. RSC Advances, 2016, 6: 87373-87379. (SCI, Q2)
34. Wei Zhu, Ying-Hua Gao, Zhi-Long Chen*, et al. Synthesis and evaluation of new 5-aminolevulinic acid derivatives as prodrugs of protoporphyrin for photodynamic therapy. Photochemical & Photobiological Sciences. 2017, 16: 1623-1630. (SCI, Q2)
35. Ping-Yong Liao, Xinrong Wang, Zhi-Long Chen*, et al. Synthesis, photophysical properties and biological evaluation of b-alkylaminoporphyrin for photodynamic therapy. Bioorganic & Medicinal Chemistry, 2016, 24(22): 6040-6047. (SCI, Q2)
36. Xiaolu Bao, Weibo Zhu, Zhi-Long Chen*, et al. Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs. Bioorganic & Medicinal Chemistry, 2016, 24(9): 2023-2031. (SCI, Q2)
International Collaboration:
We have collaborations with scholars from Ireland, England, Croatia, Russia, Vietnam, Burma, et al which were supported by grants from Chinese central government and Shanghai city government.
Team:
We have a team more than 30 persons, including 2 assistants of PhD, 2 postdoctors, 8 Ph.D students and 14 Master students, 5 international students, 7 technicians.
Labs:
We have more than 300 m2 organic chemistry labs and biological labs in the University and 300 m2 outside the University.
Position Opportunity:
We accept students to our group to finish their Master degree and Ph. D.
Postdoctoral research fellows and visiting scholars are also welcome.
Connecting Information:
E-mail: zlchen1967@qq.com; zhlchen@dhu.edu.cn;
Phone: 0086-21-67792654;
Address：Room 4092，Building 4, 2999 North Songjiang Renmin Road, Songjiang District, Shanghai, China. Postcode: 201620